ETFs positioned on Merck & Co., Inc.

Name Weight AuM 1st Jan change Investor Rating
14.34% 380 M€ +10.27% -
5.61% 20 M€ +16.38% -
2.85% 9 M€ -.--% -
2.80% 2 M€ -.--% -
2.63% 5 M€ -72.95% -
2.08% 7 M€ +12.54%
1.96% 16 M€ -3.37%
1.96% 1 M€ +11.94% -
1.96% 3 M€ +7.32% -
1.96% 13 M€ -.--% -
1.95% 2 M€ -.--%
1.91% 139 M€ +25.86%
1.84% 442 M€ +15.58%
1.50% 9 M€ -4.31% -
1.43% 435 M€ +20.44%
1.40% 273 M€ +11.32%
1.35% 2 M€ +14.69% -
1.17% 13 M€ -.--% -
1.17% 4 M€ -.--% -
1.17% 3 M€ +15.16% -
1.13% 92 M€ +0.06% -
1.08% 11 M€ +19.99%
1.05% 36 M€ -.--%
Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).
Employees
71,000
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart MERCK-CO-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
101.25USD
Average target price
129.97USD
Spread / Average Target
+28.36%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. ETFs Merck & Co., Inc.